Search results
Results From The WOW.Com Content Network
Number of employees. 354. Website. sangamo .com. Footnotes / references. [1] President and CEO Sandy Macrae in 2018. Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
A bevy of Sangamo Therapeutics news for Tuesday has SGMO stock flying high today.Source: Shutterstock Sangamo Therapeutics (NASDAQ:SGMO) starts off the day by announcing a new deal to increase its ...
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease. As ...
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat ...
Amgen Inc. Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5] The name "AMGen" is a portmanteau of the ...
In February 2020, Biogen and Sangamo Therapeutics announced a global licensing deal to develop compounds for neuromuscular and neurological diseases. In September 2020, Biogen Inc. made a $10 million deposit in OneUnited Bank to provide more capital to fund home loans and commercial development in Black communities.
Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
A look at the shareholders of Sangamo Therapeutics Inc (NASDAQ:SGMO) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...